TL;DR
This systematic review and meta-analysis of nearly 500,000 participants reveals that Isolated Diastolic Hypertension (IDH)—high diastolic pressure despite normal systolic pressure—is a significant risk factor for major cardiovascular events and strokes. The risk is particularly pronounced in adults under 55 and Asian populations, suggesting that "bottom number" hypertension should not be ignored in clinical practice.
What Problem Does This Paper Address?
Hypertension is usually defined by two numbers: systolic (the "top" number) and diastolic (the "bottom" number). While systolic hypertension is a well-known killer, Isolated Diastolic Hypertension (IDH)—defined here as a systolic blood pressure < 140 mmHg but a diastolic pressure ≥ 90 mmHg—has historically been neglected.
Clinicians and researchers have long debated whether IDH actually increases the risk of heart disease or death. Conflicting guidelines from major organizations (like the ACC/AHA vs. the ESC) have only added to the confusion. This paper aims to settle the debate by aggregating data from multiple long-term cohort studies to determine if IDH is a true independent risk factor for cardiovascular mortality and various types of stroke.
Methods
The authors conducted a systematic review and meta-analysis following PRISMA and MOOSE guidelines. They searched major medical databases (PubMed, Embase, Cochrane Library, and Web of Science) for cohort studies published through July 2021.
Key methodological features included:
- Standardized Definition: They focused on the 2018 European Society of Cardiology (ESC) definition of IDH (SBP < 140 and DBP ≥ 90 mmHg).
- Statistical Modeling: They used random-effects models to calculate pooled Hazard Ratios (HRs) and 95% Confidence Intervals (CIs).
- Quality Assessment: The Newcastle–Ottawa scale was used to ensure the included studies were of high methodological quality.
- Subgroup Analysis: To find the "why" behind the data, they stratified results by age, geographic location, and blood pressure measurement methods.
Datasets
The study synthesized data from 15 cohort studies (spanning 13 articles).
- Total Participants: 489,814 individuals.
- Follow-up Duration: Ranging from 4.3 to 29 years.
- Geographic Diversity: Studies included populations from Asia (China, Japan, Iran), the United States, and Europe (Finland, UK, Sweden).
Key Insights and Ideas
- The "Young Adult" Risk: One of the most striking findings is that IDH is significantly more dangerous for younger patients (mean age ≤ 55). In older populations, systolic pressure tends to be a better predictor of risk, but in younger adults, an elevated diastolic pressure is a major red flag.
- Geographic Disparity: The association between IDH and cardiovascular events was statistically significant in Asian populations but not in American or European subgroups. The authors suggest this might be due to differences in awareness, treatment rates, or genetic predispositions.
- Stroke Specificity: IDH showed a stronger correlation with hemorrhagic stroke (bleeding in the brain) than with ischemic stroke (clots). This suggests that high diastolic pressure may put specific types of mechanical stress on the cerebral vasculature.
- Measurement Matters: The researchers found that the method of measuring blood pressure (mercury sphygmomanometer vs. automatic digital monitor) contributed to the heterogeneity of the results, highlighting the need for standardized clinical protocols.
Key Results
The meta-analysis found that compared to people with normal blood pressure, those with IDH had:
- 28% higher risk of composite cardiovascular events (HR 1.28).
- 45% higher risk of cardiovascular mortality (HR 1.45).
- 44% higher risk of all-cause stroke (HR 1.44).
- 64% higher risk specifically for hemorrhagic stroke (HR 1.64).
Crucially, IDH was not significantly associated with an increase in all-cause mortality or ischemic stroke. In the subgroup analysis, the increased risk for composite CV events remained significant for those ≤ 55 years old and those in Asia, but disappeared for the elderly and Western populations.
Limitations and Future Work
The authors acknowledge several limitations:
- Definition Inconsistency: While they standardized to the ESC definition, the primary studies they pulled from may have had slight variations in how they recorded data.
- Heterogeneity: There was significant variation between studies, particularly regarding how blood pressure was measured and which confounding variables (like diet or exercise) were adjusted for.
- Lack of Clinical Trials: While this study shows a correlation between IDH and risk, there is still a lack of randomized controlled trials (RCTs) specifically testing whether treating IDH with medication actually reduces these risks.
Future Direction: The authors call for more age-stratified research and clinical trials to determine the cost-effectiveness of pharmacological intervention for IDH, especially in younger, asymptomatic adults.
Summary updated